Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Spironolactone Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Congenital Heart Disease, Heart Failure, Endomyocardial Fibrosis
Interventions
Spironolactone 25mg, Placebo
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Transplant, Liver
Interventions
Spironolactone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced May 22, 2026, 5:24 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Placebo, Spironolactone
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced May 22, 2026, 5:24 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Hypertension
Interventions
spironolactone, amiloride
Drug
Lead sponsor
VA Salt Lake City Health Care System
Federal
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced May 22, 2026, 5:24 AM EDT
Not listed Early Phase 1 Interventional
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Topical spironolactone ophthalmic solution, 0.005 mg/cc, Placebo
Drug
Lead sponsor
Richard W Yee, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Bioavailability Heathy Volunteers
Interventions
FDC (24 mg ER torsemide and 30 mg Spironolactone) without food, FDC (24 mg ER torsemide and 30 mg Spironolactone) with food
Combination Product
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced May 22, 2026, 5:24 AM EDT
Withdrawn Phase 4 Interventional
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis
Interventions
Spironolactone, L-arginine, Placebo
Drug · Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced May 22, 2026, 5:24 AM EDT
Recruiting Phase 4 Interventional
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Spironolactone 25mg, Aldosterone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
ST Elevation Myocardial Infarction, Non ST Elevation Myocardial Infarction
Interventions
Colchicine, Spironolactone, SYNERGY Bioabsorbable Polymer Drug-Eluting Stent, Colchicine-Placebo, Spironolactone-Placebo
Drug · Device
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
7,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Bakersfield, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Heart Failure
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced May 22, 2026, 5:24 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Obstructive Sleep Apnea, Resistant Hypertension, Hyperaldosteronism
Interventions
Spironolactone, BP medication uptitration
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Heart Failure
Interventions
CLP, Spironolactone
Drug
Lead sponsor
Sorbent Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Spironolactone 100mg, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Precocious Puberty
Interventions
Spironolactone, Testolactone, Deslorelin
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 22, 2026, 5:24 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced May 22, 2026, 5:24 AM EDT
Withdrawn Phase 4 Interventional
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Spironolactone
Drug
Lead sponsor
Dawnmarie DeFazio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced May 22, 2026, 5:24 AM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan plus Spironolactone, Ambrisentan plus Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Spironolactone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced May 22, 2026, 5:24 AM EDT
Not listed Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Chronic Lung Disease, Bronchopulmonary Dysplasia
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
West Virginia University Healthcare
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hypertension, Diabetes, Cardiovascular Disease
Interventions
Carvedilol, Spironolactone, Usual care
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced May 22, 2026, 5:24 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 5:24 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Preeclampsia, Gestational Hypertension
Interventions
spironolactone 25 mg orally once daily, Placebo tablet to match spironolactone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Healthy Participants
Interventions
Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris, Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced May 22, 2026, 5:24 AM EDT